The Human Variable 

RAVYNS™ estimates how harm becomes invisible through coerced yielding, systemic neglect, and deliberate sabotage, translating survivor intuition into measurable evidence

The COVID-19 pandemic has added another layer of immune instability through persistent inflammation, viral reactivations, and population-wide biologic stress . CRATE™ converts these complex dynamics into actionable modeling signals to inform future prevention strategy

When corrected through the US-CCUC™ framework, the combined burden of the ten most prominent infection-associated chronic conditions is estimated to affect approximately 75–90 million Americans, with 25–35 million individuals experiencing multiple overlapping conditions. Long COVID alone likely affects a population approaching 65 million adults over time when accounting for diagnostic undercounting and relapsing disease trajectories.

The Cultural Gendered Patriarchy Index (CGPI), developed by CYNAERA (2025), is the first cross-national system designed to quantify the effect of patriarchy on male diagnostic rates. By integrating data from 180 countries—including global gender indices, masculinity scales, health-seeking behavior datasets, and IACC prevalence studies—we reveal that millions of men are statistically invisible.

A Nobel-scale leap, built outside the system. This isn’t just another CRISPR project. CYNAERA’s AI-powered gene editing platform was designed by a patient, for patients—modeling remission across millions of synthetic profiles to restore immune stability in infection-associated chronic conditions like Long COVID, ME/CFS, and MCAS. It cuts years off clinical trial timelines. It eliminates $5–10 million in early development costs. It’s scalable and ethical globally. AI meets bio

Contrary to the conventional framing of remission as spontaneous or unachievable, this framework presents remission as a predictable biological outcome, emerging from synchronized interventions across immune, hormonal, mitochondrial, and environmental axes. The CYNAERA Remission Pathway™ outlines a five-phase stabilization and recovery model, while the STAIR: Stable Method™ offers pre-intervention protection for hypersensitive subgroups, including those with mast cell reacti